<DOC>
	<DOCNO>NCT01518348</DOCNO>
	<brief_summary>To evaluate diagnostic performance ( primary ) safety ( secondary ) seven T.R.U.E . Test Panel 3.2 allergen : Gold sodium thiosulfate , Hydrocortisone-17-butyrate , Bacitracin , Parthenolide , Methyldibromoglutaronitrile , Disperse blue 106 , Bronopol pediatric subject 6-18 year age suspect contact dermatitis base symptom clinical history .</brief_summary>
	<brief_title>Clinical Evaluation T.R.U.E . TEST Panel 3.2 Children Adolescents</brief_title>
	<detailed_description>The study population include least 100 consecutive subject 6-17 year age suspect contact dermatitis base symptom clinical history . Study subject must otherwise healthy fulfill entry criterion . Visit 1 ( Day 0 ) : Informed Consent , Inclusion/Exclusion Criteria Assessment , Medical Medicine History , Pregnancy Test ( female subject child-bearing potential ) , Panel Placement.Visit 2 ( Day 2 ) : Panel Removal , Panel Adhesion Irritation Assessment , AE Concomitant Medication Review.Visit 3 ( Day 3- approximately 72 hour placement ) : Skin Reactions Assessed Scored . Adverse Event Concomitant Medication Review.Visit 4 ( Day 4 approximately 96 hour placement ) : Skin Reactions Assessed Scored . Adverse Event Concomitant Medication Review.Visit 5 ( Day 7±1 ) : Skin Reaction Assessed Scored . AE Concomitant Medication Review . Visit 6 ( Day 21±2 ) : Skin Reaction Assessed Scored . AE Concomitant Medication Review . Visit perform via phone call , unless investigator determines subject see clinic . Primary Endpoint : Frequency characterization positive reaction per allergen . Secondary Endpoint : Prevalence late persistent reaction , irritation , adhesion , subject-reported itching burning , adverse event .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<criteria>Symptoms history potentially consistent allergic contact dermatitis base symptom clinical history ( i.e. , subject visit clinic/physician diagnose , treat resolve condition ) . Children adolescents 6 18 year age , general good health . Adolescent females 15 year age old ( menarche ) must consent urine pregnancy test ; urine test result must negative study inclusion . Informed consent must sign understood subject . If age , informed consent must sign understood parent legal guardian , consistent institutional , local national regulation . Topical corticosteroid treatment last 7 day near test area . Systemic treatment corticosteroid immunosuppressive last 7 day . Subjects currently receive ( receive previous 3 week ) investigational drug , treatment device , participate another clinical study . Treatment ultraviolet ( UV ) light ( include tan ) previous 3 week . Acute dermatitis outbreak dermatitis near test area back . Subjects unable comply activity restriction ( e.g. , protect test panel excess moisture due shower vigorous activity ) . Subjects unable unwilling comply multiple return visit . Female subject 15 year age ( onset menarche ) old unable consent urine pregnancy test , positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Patch Test</keyword>
	<keyword>Contact Dermatitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Children</keyword>
	<keyword>PREA</keyword>
</DOC>